Treatment Information

Back

Rectal Cancer treatment details. Chemotherapy.

Haukeland University Hospital, Bergen, Norway.

Survival: monthsCountry:Norway
Toxiciy Grade:4City/State/Province:Bergen
Treatments:ChemotherapyHospital:Haukeland University Hospital
Drugs:Journal:Link
Date:Jan 2004

Description:

Patients: This Phase II study involved 85 patients with metastatic colorectal cancer.

Treatment: The treatment consisted of three chemotherapy drugs – oxaliplatin (eloxatin), fluorouracil adrucil), and folinic acid (leucovorin).

Toxicity: Neutropenia was the main adverse event, with grade 3 to 4 toxicity in 58% of patients. Febrile neutropenia developed in seven patients. Nonhematologic toxicity consisted mainly of neuropathy (grade 3 in 11 patients and grade 2 in another 27 patients). Other grade 3-4 toxicities included: myocardial ischemia and nausea/vomiting. Nineteen patients were hospitalized because of probable treatment-related toxicity.

Results: The median overall survival was 16.1 months.

Support: This study was partially supported by Sanofi Winthrop. Oxaliplatin is manufactured by Sanofi Winthrop.

Correspondence: H. Sorbye, MD





Back